**Supplementary Table 1 (Online Resource 2)**

**Tumour compartment transcriptomics demonstrate the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identify the MAPK/ERK pathway as novel therapeutic target**

 John R. Apps1,2,\*, Gabriela Carreno1,Jose Mario Gonzalez-Meljem1,3, Scott Haston1, Romain Guiho1, Julie E. Cooper1, Saba Manshaei1, Nital Jani4, Annett Hölsken5, Benedetta Pettorini6, Robert J. Beynon7, Deborah M. Simpson7, Helen C. Fraser1, Ying Hong8, Shirleen Hallang9, Thomas J. Stone1,2, Alex Virasami2, Andrew M. Donson10, David Jones11, Kristian Aquilina12, Helen Spoudeas13, Abhijit R. Joshi14, Richard Grundy15, Lisa CD Storer15, Márta Korbonits16, David A. Hilton17, Kyoko Tossell18, Selvam Thavaraj19, Mark A. Ungless18, Jesus Gil18, Rolf Buslei5,20, Todd Hankinson10, Darren Hargrave21, Colin Goding22, Cynthia L. Andoniadou23,24, Paul Brogan8,25, Thomas S. Jacques1,2, Hywel J. Williams4 and Juan Pedro Martinez-Barbera1,\*

1) Developmental Biology and Cancer Programme, Birth Defects Research Centre, UCL Great Ormond Street Institute of Child Health, University College London, London, UK

2) Histopathology Department, Great Ormond Street Hospital NHS Trust, London, UK

3) Basic Research Department, National Institute of Geriatrics, Mexico City, Mexico

4) Centre for Translational Omics - GOSgene, Genetics and Genomic Medicine Programme, UCL Institute of Child Health, University College London, London, UK

5) Department of Neuropathology, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany

6) Alder Hey Children’s Hospital NHS Foundation Trust, Liverpool, UK

7) Centre for Proteome Research, Institute of Integrative Biology, University of Liverpool, UK

8) Infection, Immunity and Inflammation Programme, UCL Great Ormond Street Institute of Child Health, University College London, London, UK

9) Centre for Craniofacial and Regenerative Biology, King's College London, London, UK

10) Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado

11) German Cancer Research Center (DKFZ), Heidelberg, Germany

12) Neurosurgery Department, Great Ormond Street Hospital NHS Trust, London, UK

13) Endocrinology Department, Great Ormond Street Hospital NHS Trust, London, UK

14) Laboratory Medicine, Royal Victoria Infirmary, Newcastle, UK

15) Children’s Brain Tumour Research Centre, University of Nottingham, Nottingham, UK

16) William Harvey research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University, London, UK

17) Pathology Department, Plymouth Hospitals NHS Trust, Plymouth, UK

18) MRC London Institute of Medical Sciences, Imperial College London, London, UK

19) Head and Neck Pathology, Dental Institute, King's College London, London, UK

20) Institute of Pathology, Klinikum Sozialstiftung Bamberg, Bamberg, Germany

21) Haematology and Oncology department, Great Ormond Street Hospital NHS Trust, London, UK

22) Ludwig Institute for Cancer Research, Oxford University, Old Road Campus, Headington, Oxford, UK

23) Centre for Craniofacial and Regenerative Biology, King’s College London, Guy’s Hospital, Floor 27 Tower Wing, London, UK

24) Department of Internal Medicine III, Technische Universität Dresden, Fetscherstaße 74, 01307 Dresden, Germany

25) Rheumatology department, Great Ormond Street Hospital NHS Trust, London, UK

\* Corresponding authors: John Apps [j.apps@ucl.ac.uk](mailto:j.apps@ucl.ac.uk), JP Martinez-Barbera, [j.martinez-barbera@ucl.ac.uk](mailto:j.martinez-barbera@ucl.ac.uk). +44 (0) 207 905 2821

Supplementary Table 1. Characteristics of samples included in the RNA Sequencing study.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Sample ID | Type | Age of patient at sample collection | Tumour content  (% nuclear) | Glial reactive tissue | Wet keratin | *CTNNB1* mutation | *CTNNB1* RNA mutation allele frequency (%) |
| JA002a | ACP | 10yrs | 60 | Yes | Prominent | Ser37Phe | 25 |
| JA004a | ACP | 10yrs | 40 | Yes | Minimal | Ser37Phe | 16 |
| JA005b | ACP | 13yrs | 60 | Yes | Minimal | Nob | 0 |
| JA008 | ACP | 8yrs | 60 | NA | Prominent | Gly34Arg | 27 |
| JA009 | ACP | 13yrs | 90 | NA | Prominent | Ser37Phe | 48 |
| JA010 | ACP | 13yrs | 40 | Yes | None | Asp32Gly | 6 |
| JA011c | ACP | 15yrs | 20 | Yes | Minimal | Gly34Argc | 5c |
| JA013 | ACP | 8yrs | 90 | No | None | Thr31Ile | 47 |
| JA014 | ACP | 3yrs | 90 | No | None | Ser45Phe | 42 |
| JA020 | ACP | 7yrs | 70 | Yes | None | Ser37Phe | 9 |
| JA023 | ACP | 16yrs | 90 | No | Prominent | Thr31Ile | 41 |
| JA026 | ACP | 3yrs | 90 | No | Prominent | Gly34Arg | 37 |
| JA029 | ACP | 8yrs | 70 | Yes | Prominent | Gly34Glu | 13 |
| JA030 | ACP | 2yrs | 90 | No | None | Gly34Glu | 42 |
| JA036 | NFPA | adult | 0 | NA | None | No | 0 |
| JA037 | NFPA | adult | 0 | NA | None | No | 0 |
| JA038 | NFPA | adult | 0 | NA | None | No | 0 |
| JA051 | ACP | 50yrs | 80 | Yes | None | Ser33Cys | 36 |
| JA053 | ACP | 8.8yrs | 80 | No | Prominent | Asp32Arg | 41 |
| JA054 | ACP | 13.1yrs | NA | NA | NA | Asp32Tyr | 13 |
| JA056 | ACP | 8.4yrs | 80 | No | Prominent | Ser33Cys | 36 |
| JA058 | Fetal Pituitary | 21/40 GA | 0 | No | None | No | 0 |
| JA059 | Fetal Pituitary | 21/40 GA | 0 | No | None | No | 0 |
| JA060 | Fetal Pituitary | 21/40 GA | 0 | No | None | No | 0 |

ACP: Adamantinomatous craniopharyngioma; NFPA: Non-functioning pituitary adenoma; GA: Gestational age; NA: Not assessed.

a: JA002 and JA004 were two separate samples collected from one tumour in the same surgery. b: *CTNNB1* mutation not detected by RNA sequencing or targeted next generation sequencing. c: *CTNNB1* mutation not detected by RNA sequencing but detected by targeted next generation sequencing of DNA of adjacent frozen tumour sample.